Skip to Content
01. Doctor Overview

Doctor Overview

Dr. Pasi A. Jänne is a thoracic medical oncologist at the Dana-Farber Cancer Institute. He also is a professor at Harvard Medical School and the director of the Lowe Center for Thoracic Oncology, as well as director of the Belfer Center for Applied Cancer Science. Dr. Jänne’s main research interests include the therapeutic relevance of oncogenic alterations in lung cancer. He is affiliated with the cancer genetics and lung cancer programs at Dana-Farber/Harvard Cancer Center.

Dr. Jänne has contributed to a number of peer-reviewed journals as an author and co-author. Some of those publications include The New England Journal of Medicine, Oncology, The Journal of the National Cancer Institute, Science, and Cancer Research.

02. Fast Facts

Doctor Fast Facts

Main Specialty: Thoracic Oncology

Other Interests & Specialties: Epidermal growth factor receptor targeted therapies, lung cancer, targeted therapies and translational medicine.

Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Certification in Medical Oncology, George P. Canellos Award for Excellence in Clinical Investigation and Patient Care, American Society of Clinical Oncology’s Merit Award, Hope Now Award for Lung Cancer Research, Team Science Award, Richard and Hinda Rosenthal Memorial Award, Research Excellence Award

Education & Experience:

  • Medical Degree from University of Pennsylvania School of Medicine
  • Residency in Internal Medicine at Brigham and Women’s Hospital, Internal Medicine
  • Fellowship in Hematology & Oncology at Dana-Farber/Partners Cancer Care
03. Publications


Imaging of lung cancer in the era of molecular medicine. Academic Radiology. April 2011;18(4): 424-36. doi: 10.1016/j.acra.2010.10.020

Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-Term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. December 2018. doi: 10.1002/cncr.31891

Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Research. September 2002; 62(18): 5242-7.

04. Mesothelioma Clinical Trials

Mesothelioma Clinical Trials by Pasi A. Jänne, MD, PhD

Dr. Jänne is associated with the following clinical trials:

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Conditions: Mesothelioma, Mesothelioma, Malignant

Last Updated: December 23, 2011

Status: Completed

Locations: Chicago, IL. Boston, MA. Boston, MA.

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms

Last Updated: June 4, 2013

Status: Completed

Locations: Chicago, IL. Boston, MA.